ABCL

#1697
AbCellera Biologics Inc. - Common Shares
6.1 8 USD
+7.85%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
6.05
6.22
Range Annuel
1.98
6.52
Changement quotidien
+7.85%
Changement Mensuel
+59.28%
Evolution sur 6 mois
+71.19%
Changement Annuel
+202.94%
Clôture Précédente
5.7 3
Open
6.0 6
Low
6.0 5
High
6.2 2
Volume
1 579
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques
Trimestriel Annuel
  • Market Capitalization 1.89 B
  • Employee 562
  • Founded 2012
  • CEO Carl Hansen
  • Website www.abcellera.com
  • Headquarter British Columbia, Canada
  • FIGI BBG00LLW2MF2
  • Industry Biotechnologies
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
-6.98
ratio cours/chiffre d'affaires
13.6

AbCellera Biologics Inc. - Common Shares

AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.

Nouvelles